Top

Published in:

01-03-2018 | Review

Regulation, signalling and functions of hormonal peptides in pulmonary vascular remodelling during hypoxia

Authors: Priya Gaur, Supriya Saini, Praveen Vats, Bhuvnesh Kumar

Published in: Endocrine | Issue 3/2018

Abstract

Hypoxic state affects organism primarily by decreasing the amount of oxygen reaching the cells and tissues. To adjust with changing environment organism undergoes mechanisms which are necessary for acclimatization to hypoxic stress. Pulmonary vascular remodelling is one such mechanism controlled by hormonal peptides present in blood circulation for acclimatization. Activation of peptides regulates constriction and relaxation of blood vessels of pulmonary and systemic circulation. Thus, understanding of vascular tone maintenance and hypoxic pulmonary vasoconstriction like pathophysiological condition during hypoxia is of prime importance. Endothelin-1 (ET-1), atrial natriuretic peptide (ANP), and renin angiotensin system (RAS) function, their receptor functioning and signalling during hypoxia in different body parts point them as disease markers. In vivo and in vitro studies have helped understanding the mechanism of hormonal peptides for better acclimatization to hypoxic stress and interventions for better management of vascular remodelling in different models like cell, rat, and human is discussed in this review.

J.A. Dempsey, W.G. Reddan, M.L. Birnbaum, H.V. Forster, J.S. Thoden, R.F. Grover, J. Rankin, Effects of acute through life-long hypoxic exposure on exercise pulmonary gas exchange. Respir. Physiol. 13(1), 62–89 (1971)PubMedCrossRef

R. Ashack, M.O. Farber, M.H. Weinberger, G.L. Robertson, N.S. Fineberg, F. Manfredi, Renal and hormonal responses to acute hypoxia in normal individuals. J. Lab. Clin. Med. 106(1), 12–16 (1985)PubMed

F.H. Al-Hashem, The effect of high altitude on blood hormones in male Westar rats in South western Saudi Arabia. Am. J. Environ. Sci. 6(3), 268–274 (2010)CrossRef

N. Mason, The physiology of high altitude: an introduction to the cardio-respiratory changes occurring on ascent to altitude. Curr. Anaesth. Crit. Care 11(1), 34–41 (2000)CrossRef

E.R. Swenson, T.B. Duncan, S.V. Goldberg, G. Ramirez, S. Ahmad, R.B. Schoene, Diuretic effect of acute hypoxia in humans: relationship to hypoxic ventilatory responsiveness and renal hormones. J. Appl. Physiol. 78(2), 377–383 (1995)PubMedCrossRef

P. Ariyaratnam, M. Loubani, A.H. Morice, Hypoxic pulmonary vasoconstriction in humans. BioMed. Res. Int. 2013, 623684 (2013). https://doi.org/10.1155/2013/623684 PubMedPubMedCentralCrossRef

P.I. Aaronson, T.P. Robertson, G.A. Knock, S. Becker, T.H. Lewis, V. Snetkov, J.P. Ward, Hypoxic pulmonary vasoconstriction: mechanisms and controversies. J. Physiol. 570(Pt 1), 53–58 (2006). https://doi.org/10.1113/jphysiol.2005.098855 PubMedCrossRef

K.R. Stenmark, K.A. Fagan, M.G. Frid, Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ. Res. 99(7), 675–691 (2006). https://doi.org/10.1161/01.RES.0000243584.45145.3f PubMedCrossRef

A. Hussain, M.S. Suleiman, S.J. George, M. Loubani, A. Morice, Hypoxic pulmonary vasoconstriction in humans: tale or myth. Open. Cardiovasc. Med. J. 11, 1–13 (2017). https://doi.org/10.2174/1874192401711010001 PubMedPubMedCentralCrossRef

10.

A.B. Lumb, P. Slinger, Hypoxic pulmonary vasoconstriction: physiology and anesthetic implications. Anesthesiology 122(4), 932–946 (2015). https://doi.org/10.1097/ALN.0000000000000569 PubMedCrossRef

11.

M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto, T. Masaki, A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332(6163), 411–415 (1988). https://doi.org/10.1038/332411a0 PubMedCrossRef

12.

D. Xu, N. Emoto, A. Giaid, C. Slaughter, S. Kaw, D. deWit, M. Yanagisawa, ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78(3), 473–485 (1994)PubMedCrossRef

13.

T.J. Opgenorth, J.R. Wu-Wong, K. Shiosaki, Endothelin-converting enzymes. FASEB J. 6(9), 2653–2659 (1992)PubMedCrossRef

14.

T. Sakurai, M. Yanagisawa, Y. Takuwa, H. Miyazaki, S. Kimura, K. Goto, T. Masaki, Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348(6303), 732–735 (1990). https://doi.org/10.1038/348732a0 PubMedCrossRef

15.

V.J. Harrison, R. Corder, E.E. Anggard, J.R. Vane, Evidence for vesicles that transport endothelin-1 in bovine aortic endothelial cells. J. Cardiovasc. Pharmacol. 22(Suppl 8), S57–S60 (1993)PubMedCrossRef

16.

M.J. Boscoe, A.T. Goodwin, M. Amrani, M.H. Yacoub, Endothelins and the lung. Int. J. Biochem. Cell. Biol. 32(1), 41–62 (2000)PubMedCrossRef

17.

Y. Miyoshi, Y. Nakaya, T. Wakatsuki, S. Nakaya, K. Fujino, K. Saito, I. Inoue, Endothelin blocks ATP-sensitive K+ channels and depolarizes smooth muscle cells of porcine coronary artery. Circ. Res. 70(3), 612–616 (1992)PubMedCrossRef

18.

M.J. Kuchan, J.A. Frangos, Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultured endothelial cells. Am. J. Physiol. 264(1 Pt 2), H150–H156 (1993)PubMed

19.

K. Sato, Y. Morio, K.G. Morris, D.M. Rodman, I.F. McMurtry, Mechanism of hypoxic pulmonary vasoconstriction involves ET(A) receptor-mediated inhibition of K(ATP) channel. Am. J. Physiol. Lung Cell. Mol. Physiol. 278(3), L434–L442 (2000)PubMedCrossRef

20.

M.J. Horgan, J.M. Pinheiro, A.B. Malik, Mechanism of endothelin-1-induced pulmonary vasoconstriction. Circ. Res. 69(1), 157–164 (1991)PubMedCrossRef

21.

K. Nakanishi, F. Tajima, Y. Nakata, H. Osada, S. Tachibana, T. Kawai, C. Torikata, T. Suga, K. Takishima, T. Aurues, T. Ikeda, Expression of endothelin-1 in rats developing hypobaric hypoxia-induced pulmonary hypertension. Lab. Invest. 79(11), 1347–1357 (1999)PubMed

22.

D.J. Stewart, R.D. Levy, P. Cernacek, D. Langleben, Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann. Intern. Med. 114(6), 464–469 (1991)PubMedCrossRef

23.

S. Oparil, S.J. Chen, Q.C. Meng, T.S. Elton, M. Yano, Y.F. Chen, Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat. Am. J. Physiol. 268(1 Pt 1), L95–L100 (1995)PubMed

24.

V.S. DiCarlo, S.J. Chen, Q.C. Meng, J. Durand, M. Yano, Y.F. Chen, S. Oparil, ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. Am. J. Physiol. 269(5 Pt 1), L690–L697 (1995)PubMed

25.

S.T. Bonvallet, M.R. Zamora, K. Hasunuma, K. Sato, N. Hanasato, D. Anderson, K. Sato, T.J. Stelzner, BQ123, an ETA-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats. Am. J. Physiol. 266(4 Pt 2), H1327–H1331 (1994)PubMed

26.

W. Johnson, A. Nohria, L. Garrett, J.C. Fang, J. Igo, M. Katai, P. Ganz, M.A. Creager, Contribution of endothelin to pulmonary vascular tone under normoxic and hypoxic conditions. Am. J. Physiol. Heart Circ. Physiol. 283(2), H568–H575 (2002). https://doi.org/10.1152/ajpheart.00099.2001 PubMedCrossRef

27.

I. Pham, G. Wuerzner, J.P. Richalet, S. Peyrard, M. Azizi, Endothelin receptors blockade blunts hypoxia-induced increase in PAP in humans. Eur. J. Clin. Invest. 40(3), 195–202 (2010). https://doi.org/10.1111/j.1365-2362.2010.02254.x PubMedCrossRef

28.

P.A. Modesti, S. Vanni, M. Morabito, A. Modesti, M. Marchetta, T. Gamberi, F. Sofi, G. Savia, G. Mancia, G.F. Gensini, G. Parati, Role of endothelin-1 in exposure to high altitude: acute mountain sickness and endothelin-1 (ACME-1) study. Circulation 114(13), 1410–1416 (2006). https://doi.org/10.1161/CIRCULATIONAHA.105.605527 PubMedCrossRef

29.

R.D. Seheult, K. Ruh, G.P. Foster, J.D. Anholm, Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude. Respir. Physiol. Neurobiol. 165(2–3), 123–130 (2009). https://doi.org/10.1016/j.resp.2008.10.005 PubMedCrossRef

30.

R. Naeije, S. Huez, M. Lamotte, K. Retailleau, S. Neupane, D. Abramowicz, V. Faoro, Pulmonary artery pressure limits exercise capacity at high altitude. Eur. Respir. J. 36(5), 1049–1055 (2010). https://doi.org/10.1183/09031936.00024410 PubMedCrossRef

31.

D. Kylhammar, G. Radegran, The principal pathways involved in the in vivo modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and pulmonary hypertension. Acta Physiol. 219(4), 728–756 (2017). https://doi.org/10.1111/apha.12749 CrossRef

32.

V.V. Kuzkov, M.Y. Kirov, M.A. Sovershaev, V.N. Kuklin, E.V. Suborov, K. Waerhaug, L.J. Bjertnaes, Extravascular lung water determined with single transpulmonary thermodilution correlates with the severity of sepsis-induced acute lung injury. Crit. Care. Med. 34(6), 1647–1653 (2006). https://doi.org/10.1097/01.CCM.0000218817.24208.2E PubMedCrossRef

33.

I. Kosmidou, D. Karmpaliotis, A.J. Kirtane, H.V. Barron, C.M. Gibson, Vascular endothelial growth factors in pulmonary edema: an update. J. Thromb. Thrombolysis 25(3), 259–264 (2008). https://doi.org/10.1007/s11239-007-0062-4 PubMedCrossRef

34.

A.P. Comellas, A. Briva, Role of endothelin-1 in acute lung injury. Transl. Res. 153(6), 263–271 (2009). https://doi.org/10.1016/j.trsl.2009.02.007 PubMedPubMedCentralCrossRef

35.

I. Pham, G. Wuerzner, J.P. Richalet, S. Peyrard, M. Azizi, Bosentan effects in hypoxic pulmonary vasoconstriction: preliminary study in subjects with or without high altitude pulmonary edema-history. Pulm. Circ. 2(1), 28–33 (2012). https://doi.org/10.4103/2045-8932.94824 PubMedPubMedCentralCrossRef

36.

C. Sartori, L. Vollenweider, B.M. Loffler, A. Delabays, P. Nicod, P. Bartsch, U. Scherrer, Exaggerated endothelin release in high-altitude pulmonary edema. Circulation 99(20), 2665–2668 (1999)PubMedCrossRef

37.

S.W. Allen, B.A. Chatfield, S.A. Koppenhafer, M.S. Schaffer, R.R. Wolfe, S.H. Abman, Circulating immunoreactive endothelin-1 in children with pulmonary hypertension. Association with acute hypoxic pulmonary vasoreactivity. Am. Rev. Respir. Dis. 148(2), 519–522 (1993). https://doi.org/10.1164/ajrccm/148.2.519 PubMedCrossRef

38.

M.P. Schneider, E.I. Boesen, D.M. Pollock, Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu. Rev. Pharmacol. Toxicol. 47, 731–759 (2007). https://doi.org/10.1146/annurev.pharmtox.47.120505.105134 PubMedPubMedCentralCrossRef

39.

B.K. Kramer, M. Bucher, P. Sandner, K.P. Ittner, G.A. Riegger, T. Ritthaler, A. Kurtz, Effects of hypoxia on growth factor expression in the rat kidney in vivo. Kidney Int. 51(2), 444–447 (1997)PubMedCrossRef

40.

K.U. Eckardt, W.M. Bernhardt, A. Weidemann, C. Warnecke, C. Rosenberger, M.S. Wiesener, C. Willam, Role of hypoxia in the pathogenesis of renal disease. Kidney Int. Suppl. 99, S46–S51 (2005). https://doi.org/10.1111/j.1523-1755.2005.09909.x CrossRef

41.

D.E. Kohan, E. Padilla, Osmolar regulation of endothelin-1 production by rat inner medullary collecting duct. J. Clin. Invest. 91(3), 1235–1240 (1993). https://doi.org/10.1172/JCI116286 PubMedPubMedCentralCrossRef

42.

V.H. Haase, Mechanisms of hypoxia responses in renal tissue. J. Am. Soc. Nephrol. 24(4), 537–541 (2013). https://doi.org/10.1681/ASN.2012080855 PubMedCrossRef

43.

A. Nir, A.L. Clavell, D. Heublein, L.L. Aarhus, J.C. Burnett Jr., Acute hypoxia and endogenous renal endothelin. J. Am. Soc. Nephrol. 4(11), 1920–1924 (1994)PubMed

44.

J.B. Heimlich, J.S. Speed, C.J. Bloom, P.M. O’Connor, J.S. Pollock, D.M. Pollock, ET-1 increases reactive oxygen species following hypoxia and high-salt diet in the mouse glomerulus. Acta Physiol. 213(3), 722–730 (2015). https://doi.org/10.1111/apha.12397 CrossRef

45.

B. Kisch, Electron microscopy of the atrium of the heart. I. Guinea pig. Exp. Med. Surg. 14(2–3), 99–112 (1956)PubMed

46.

K. Kangawa, H. Matsuo, Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem. Biophys. Res. Commun. 118(1), 131–139 (1984)PubMedCrossRef

47.

Y. Saito, Roles of atrial natriuretic peptide and its therapeutic use. J. Cardiol. 56(3), 262–270 (2010)PubMedCrossRef

48.

K.S. Misono, J.S. Philo, T. Arakawa, C.M. Ogata, Y. Qiu, H. Ogawa, H.S. Young, Structure, signaling mechanism and regulation of the natriuretic peptide receptor guanylate cyclase. FEBS J. 278(11), 1818–1829 (2011). https://doi.org/10.1111/j.1742-4658.2011.08083.x PubMedPubMedCentralCrossRef

49.

L.R. Potter, Natriuretic peptide metabolism, clearance and degradation. FEBS J. 278(11), 1808–1817 (2011). https://doi.org/10.1111/j.1742-4658.2011.08082.x PubMedPubMedCentralCrossRef

50.

O. Arjamaa, M. Nikinmaa, Hypoxia regulates the natriuretic peptide system. Int. J. Physiol. Pathophysiol. Pharmacol. 3(3), 191–201 (2011)PubMedPubMedCentral

51.

R.J. Winter, L. Zhao, T. Krausz, J.M. Hughes, Neutral endopeptidase 24.11 inhibition reduces pulmonary vascular remodeling in rats exposed to chronic hypoxia. Am. Rev. Respir. Dis. 144(6), 1342–1346 (1991). https://doi.org/10.1164/ajrccm/144.6.1342 PubMedCrossRef

52.

N.B. Standen, J.M. Quayle, K+ channel modulation in arterial smooth muscle. Acta Physiol. Scand. 164(4), 549–557 (1998). https://doi.org/10.1046/j.1365-201X.1998.00433.x PubMedCrossRef

53.

M. Kuhn, Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ. Res. 93(8), 700–709 (2003). https://doi.org/10.1161/01.RES.0000094745.28948.4D PubMedCrossRef

54.

Y.F. Chen, Atrial natriuretic peptide in hypoxia. Peptides 26(6), 1068–1077 (2005). https://doi.org/10.1016/j.peptides.2004.08.030 PubMedCrossRef

55.

O. Pauvert, S. Bonnet, E. Rousseau, R. Marthan, J.P. Savineau, Sildenafil alters calcium signaling and vascular tone in pulmonary arteries from chronically hypoxic rats. Am. J. Physiol. Lung Cell. Mol. Physiol. 287(3), L577–L583 (2004). https://doi.org/10.1152/ajplung.00449.2003 PubMedCrossRef

56.

M. Gomberg-Maitland, V. McLaughlin, M. Gulati, S. Rich, Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am. J. Cardiol. 96(9), 1334–1336 (2005). https://doi.org/10.1016/j.amjcard.2005.06.083 PubMedCrossRef

57.

H.H. Leuchte, M. Schwaiblmair, R.A. Baumgartner, C.F. Neurohr, T. Kolbe, J. Behr, Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 125(2), 580–586 (2004)PubMedCrossRef

58.

D. Wang, S. Oparil, J.A. Feng, P. Li, G. Perry, L.B. Chen, M. Dai, S.W. John, Y.F. Chen, Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension 42(1), 88–95 (2003). https://doi.org/10.1161/01.HYP.0000074905.22908.A6 PubMedCrossRef

59.

Y.S. Chun, J.Y. Hyun, Y.G. Kwak, I.S. Kim, C.H. Kim, E. Choi, M.S. Kim, J.W. Park, Hypoxic activation of the atrial natriuretic peptide gene promoter through direct and indirect actions of hypoxia-inducible factor-1. Biochem. J. 370(Pt 1), 149–157 (2003). https://doi.org/10.1042/BJ20021087 PubMedPubMedCentralCrossRef

60.

Q.L. Zhang, B.R. Cui, H.Y. Li, P. Li, L. Hong, L.P. Liu, D.Z. Ding, X. Cui, MAPK and PI3K pathways regulate hypoxia-induced atrial natriuretic peptide secretion by controlling HIF-1 alpha expression in beating rabbit atria. Biochem. Biophys. Res. Commun. 438(3), 507–512 (2013). https://doi.org/10.1016/j.bbrc.2013.07.106 PubMedCrossRef

61.

W. Forssmann, M. Meyer, K. Forssmann, The renal urodilatin system: clinical implications. Cardiovasc. Res. 51(3), 450–462 (2001)PubMedCrossRef

62.

B. Haditsch, A. Roessler, P. Krisper, H. Frisch, H.G. Hinghofer-Szalkay, N. Goswami, Volume regulation and renal function at high altitude across gender. PLoS. One 10(3), e0118730 (2015). https://doi.org/10.1371/journal.pone.0118730 PubMedPubMedCentralCrossRef

63.

R.G. Westendorp, A.N. Roos, H.G. van der Hoeven, M.Y. Tjiong, R. Simons, M. Frolich, J.H. Souverijn, A.E. Meinders, Atrial natriuretic peptide improves pulmonary gas exchange in subjects exposed to hypoxia. Am. Rev. Respir. Dis. 148(2), 304–309 (1993). https://doi.org/10.1164/ajrccm/148.2.304 PubMedCrossRef

64.

T.J. Tunny, J. van Gelder, R.D. Gordon, S.A. Klemm, S.M. Hamlet, W.L. Finn, G.M. Carney, C. Brand-Maher, Effects of altitude on atrial natriuretic peptide: the Bicentennial Mount Everest expedition. Clin. Exp. Pharmacol. Physiol. 16(4), 287–291 (1989)PubMedCrossRef

65.

A. Kawashima, K. Kubo, K. Hirai, S. Yoshikawa, Y. Matsuzawa, T. Kobayashi, Plasma levels of atrial natriuretic peptide under acute hypoxia in normal subjects. Respir. Physiol. 76(1), 79–91 (1989)PubMedCrossRef

66.

R.I. Cargill, B.J. Lipworth, Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans. Br. J. Clin. Pharmacol. 40(6), 585–590 (1995)PubMedPubMedCentralCrossRef

67.

M.C. Chappell, Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am. J. Physiol. Heart Circ. Physiol. 310(2), H137–H152 (2016). https://doi.org/10.1152/ajpheart.00618.2015 PubMedCrossRef

68.

L.C. Roksnoer, K. Verdonk, A.H. van den Meiracker, E.J. Hoorn, R. Zietse, A.H. Danser, Urinary markers of intrarenal renin-angiotensin system activity in vivo. Curr. Hypertens. Rep. 15(2), 81–88 (2013). https://doi.org/10.1007/s11906-012-0326-z PubMedCrossRef

69.

K.E. Bernstein, F.S. Ong, W.L. Blackwell, K.H. Shah, J.F. Giani, R.A. Gonzalez-Villalobos, X.Z. Shen, S. Fuchs, R.M. Touyz, A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol. Rev. 65(1), 1–46 (2013). https://doi.org/10.1124/pr.112.006809 PubMedPubMedCentralCrossRef

70.

J.T. August, D.H. Nelson, G.W. Thorn, Aldosterone. N. Engl. J. Med. 259(19), 917–923 (1958). https://doi.org/10.1056/NEJM195811062591907. contdPubMedCrossRef

71.

P.K. Mehta, K.K. Griendling, Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell. Physiol. 292(1), C82–C97 (2007). https://doi.org/10.1152/ajpcell.00287.2006 PubMedCrossRef

72.

E. Kaschina, T. Unger, Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 12(2), 70–88 (2003)PubMedCrossRef

73.

Y. Imai, K. Kuba, T. Ohto-Nakanishi, J.M. Penninger, Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ. J. 74(3), 405–410 (2010)PubMedCrossRef

74.

K.B. Brosnihan, L.A. Neves, M.C. Chappell, Does the angiotensin-converting enzyme (ACE)/ACE2 balance contribute to the fate of angiotensin peptides in programmed hypertension? Hypertension 46(5), 1097–1099 (2005). https://doi.org/10.1161/01.HYP.0000185149.56516.0a PubMedCrossRef

75.

S. Wakahara, T. Konoshita, S. Mizuno, M. Motomura, C. Aoyama, Y. Makino, N. Kato, I. Koni, I. Miyamori, Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio. Endocrinology 148(5), 2453–2457 (2007). https://doi.org/10.1210/en.2006-1287 PubMedCrossRef

76.

C.N. Bradford, D.R. Ely, M.K. Raizada, Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy. Curr. Hypertens. Rep. 12(4), 212–219 (2010). https://doi.org/10.1007/s11906-010-0122-6 PubMedPubMedCentralCrossRef

77.

R. Zhang, Y. Wu, M. Zhao, C. Liu, L. Zhou, S. Shen, S. Liao, K. Yang, Q. Li, H. Wan, Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 297(4), L631–L640 (2009). https://doi.org/10.1152/ajplung.90415.2008 PubMedCrossRef

78.

L.J. Mullins, B.R. Conway, R.I. Menzies, L. Denby, J.J. Mullins, Renal disease pathophysiology and treatment: contributions from the rat. Dis. Model. Mech. 9(12), 1419–1433 (2016). https://doi.org/10.1242/dmm.027276 PubMedPubMedCentralCrossRef

79.

J. Loeffler, J. Stockigt, W. Ganong, Effect of alpha-and beta-adrenergic blocking agents on the increase in renin secretion produced by stimulation of the renal nerves. Neuroendocrinology 10(3), 129–138 (1972)PubMedCrossRef

80.

M. Nangaku, T. Fujita, Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertens. Res. 31(2), 175–184 (2008). https://doi.org/10.1291/hypres.31.175 PubMedCrossRef

81.

H. Matsui, T. Shimosawa, K. Itakura, X. Guanqun, K. Ando, T. Fujita, Adrenomedullin can protect against pulmonary vascular remodeling induced by hypoxia. Circulation 109(18), 2246–2251 (2004). https://doi.org/10.1161/01.CIR.0000127950.13380.FD PubMedCrossRef

82.

C. Ruster, G. Wolf, Renin-angiotensin-aldosterone system and progression of renal disease. J. Am. Soc. Nephrol. 17(11), 2985–2991 (2006). https://doi.org/10.1681/ASN.2006040356 PubMedCrossRef

83.

S. Srivastava, S. Dwivedi, Significance of renin angiotensin aldosterone system (RAAS) pathway in high altitude pulmonary edema (HAPE) susceptibility. J. Clin. Mol. Endocrinol 1(3), 1–4 (2016).

84.

E.C. Fletcher, N. Orolinova, M. Bader, Blood pressure response to chronic episodic hypoxia: the renin-angiotensin system. J. Appl. Physiol. 92(2), 627–633 (2002). https://doi.org/10.1152/japplphysiol.000152.2001 PubMedCrossRef

85.

I. Hubloue, B. Rondelet, F. Kerbaul, D. Biarent, G.M. Milani, M. Staroukine, P. Bergmann, R. Naeije, M. Leeman, Endogenous angiotensin II in the regulation of hypoxic pulmonary vasoconstriction in anaesthetized dogs. Crit. Care 8(4), R163–R171 (2004). https://doi.org/10.1186/cc2860 PubMedPubMedCentralCrossRef

86.

K. Manotham, B. Ongvilawan, P. Urusopone, S. Chetsurakarn, J. Tanamai, P. Limkuansuwan, K. Tungsanga, S. Eiam-Ong, Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: a pre-/post-study. Intern. Med. J. 42(4), e33–e37 (2012)PubMedCrossRef

87.

N.J. Marcus, Y.L. Li, C.E. Bird, H.D. Schultz, B.J. Morgan, Chronic intermittent hypoxia augments chemoreflex control of sympathetic activity: role of the angiotensin II type 1 receptor. Respir. Physiol. Neurobiol. 171(1), 36–45 (2010). https://doi.org/10.1016/j.resp.2010.02.003 PubMedPubMedCentralCrossRef

88.

M.C. Lansang, S.Y. Osei, D.A. Price, N.D. Fisher, N.K. Hollenberg, Renal hemodynamic and hormonal responses to the angiotensin II antagonist candesartan. Hypertension 36(5), 834–838 (2000)PubMedCrossRef

89.

N.R. Prabhakar, G.K. Kumar, Mechanisms of sympathetic activation and blood pressure elevation by intermittent hypoxia. Respir. Physiol. Neurobiol. 174(1–2), 156–161 (2010). https://doi.org/10.1016/j.resp.2010.08.021 PubMedPubMedCentralCrossRef

90.

V. Pialoux, G.E. Foster, S.B. Ahmed, A.E. Beaudin, P.J. Hanly, M.J. Poulin, Losartan abolishes oxidative stress induced by intermittent hypoxia in humans. J. Physiol. 589(Pt 22), 5529–5537 (2011). https://doi.org/10.1113/jphysiol.2011.218156 PubMedPubMedCentralCrossRef

91.

G.E. Foster, P.J. Hanly, S.B. Ahmed, A.E. Beaudin, V. Pialoux, M.J. Poulin, Intermittent hypoxia increases arterial blood pressure in humans through a renin-angiotensin system-dependent mechanism. Hypertension 56(3), 369–377 (2010). https://doi.org/10.1161/HYPERTENSIONAHA.110.152108 PubMedCrossRef

92.

R. Tamisier, J.L. Pepin, J. Remy, J.P. Baguet, J.A. Taylor, J.W. Weiss, P. Levy, 14 nights of intermittent hypoxia elevate daytime blood pressure and sympathetic activity in healthy humans. Eur. Respir. J. 37(1), 119–128 (2011). https://doi.org/10.1183/09031936.00204209 PubMedCrossRef

93.

G.S. Gilmartin, M. Lynch, R. Tamisier, J.W. Weiss, Chronic intermittent hypoxia in humans during 28 nights results in blood pressure elevation and increased muscle sympathetic nerve activity. Am. J. Physiol. Heart Circ. Physiol. 299(3), H925–H931 (2010). https://doi.org/10.1152/ajpheart.00253.2009 PubMedPubMedCentralCrossRef

94.

G. Bao, N. Metreveli, R. Li, A. Taylor, E.C. Fletcher, Blood pressure response to chronic episodic hypoxia: role of the sympathetic nervous system. J. Appl. Physiol. 83(1), 95–101 (1997)PubMedCrossRef

95.

E.C. Fletcher, J. Lesske, J. Culman, C.C. Miller, T. Unger, Sympathetic denervation blocks blood pressure elevation in episodic hypoxia. Hypertension 20(5), 612–619 (1992)PubMedCrossRef

96.

E.C. Fletcher, G. Bao, R. Li, Renin activity and blood pressure in response to chronic episodic hypoxia. Hypertension 34(2), 309–314 (1999)PubMedCrossRef

97.

S.Y. Lam, P.S. Leung, A locally generated angiotensin system in rat carotid body. Regul. Pept. 107(1–3), 97–103 (2002)PubMedCrossRef

98.

S.Y. Lam, Y. Liu, K.M. Ng, E.C. Liong, G.L. Tipoe, P.S. Leung, M.L. Fung, Upregulation of a local renin-angiotensin system in the rat carotid body during chronic intermittent hypoxia. Exp. Physiol. 99(1), 220–231 (2014). https://doi.org/10.1113/expphysiol.2013.074591 PubMedCrossRef

99.

M. Boone, P.M. Deen, Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption. Pflug. Arch. 456(6), 1005–1024 (2008). https://doi.org/10.1007/s00424-008-0498-1 CrossRef

100.

M.E. Alfie, S. Alim, D. Mehta, E.G. Shesely, O.A. Carretero, An enhanced effect of arginine vasopressin in bradykinin B2 receptor null mutant mice. Hypertension 33(6), 1436–1440 (1999)PubMedCrossRef

101.

C.W. Bourque, S.H. Oliet, D. Richard, Osmoreceptors, osmoreception, and osmoregulation. Front. Neuroendocrinol. 15(3), 231–274 (1994). https://doi.org/10.1006/frne.1994.1010 PubMedCrossRef

102.

M.A. Knepper, Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am. J. Physiol. 272(1 Pt 2), F3–F12 (1997)PubMed

103.

C.M. Maresh, W.J. Kraemer, D.A. Judelson, J.L. VanHeest, L. Trad, J.M. Kulikowich, K.L. Goetz, A. Cymerman, A.J. Hamilton, Effects of high altitude and water deprivation on arginine vasopressin release in men. Am. J. Physiol. Endocrinol. Metab. 286(1), E20–E24 (2004). https://doi.org/10.1152/ajpendo.00332.2003 PubMedCrossRef

104.

G. Ramirez, D. Pineda, P.A. Bittle, H. Rabb, R. Rosen, D. Vesely, S. Sasaki, Partial renal resistance to arginine vasopressin as an adaptation to high altitude living. Aviat. Space Environ. Med. 69(1), 58–65 (1998)PubMed

105.

A. Takamata, H. Nose, T. Kinoshita, M. Hirose, T. Itoh, T. Morimoto, Effect of acute hypoxia on vasopressin release and intravascular fluid during dynamic exercise in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279(1), R161–R168 (2000)PubMedCrossRef

106.

F.D. Blume, S.J. Boyer, L.E. Braverman, A. Cohen, J. Dirkse, J.P. Mordes, Impaired osmoregulation at high altitude: studies on Mt Everest. Jama 252(4), 524–526 (1984)PubMedCrossRef

107.

L. Ostergaard, A. Rudiger, S. Wellmann, E. Gammella, B. Beck-Schimmer, J. Struck, M. Maggiorini, M. Gassmann, Arginine-vasopressin marker copeptin is a sensitive plasma surrogate of hypoxic exposure. Hypoxia 2, 143–151 (2014). https://doi.org/10.2147/HP.S57894 PubMedPubMedCentralCrossRef

108.

R.L. Cosby, A.M. Sophocles, J.A. Durr, C.L. Perrinjaquet, B. Yee, R.W. Schrier, Elevated plasma atrial natriuretic factor and vasopressin in high-altitude pulmonary edema. Ann. Intern. Med. 109(10), 796–799 (1988)PubMedCrossRef

109.

P. Bartsch, M. Maggiorini, W. Schobersberger, S. Shaw, W. Rascher, J. Girard, P. Weidmann, O. Oelz, Enhanced exercise-induced rise of aldosterone and vasopressin preceding mountain sickness. J. Appl. Physiol. 71(1), 136–143 (1991)PubMedCrossRef

110.

O. Pak, A. Aldashev, D. Welsh, A. Peacock, The effects of hypoxia on the cells of the pulmonary vasculature. Eur. Respir. J. 30(2), 364–372 (2007). https://doi.org/10.1183/09031936.00128706 PubMedCrossRef

111.

C. Fonseca, D. Abraham, E.A. Renzoni, Endothelin in pulmonary fibrosis. Am. J. Respir. Cell. Mol. Biol. 44(1), 1–10 (2011). https://doi.org/10.1165/rcmb.2009-0388TR PubMedCrossRef

112.

N.J. Davie, E.V. Gerasimovskaya, S.E. Hofmeister, A.P. Richman, P.L. Jones, J.T. Reeves, K.R. Stenmark, Pulmonary artery adventitial fibroblasts cooperate with vasa vasorum endothelial cells to regulate vasa vasorum neovascularization: a process mediated by hypoxia and endothelin-1. Am. J. Pathol. 168(6), 1793–1807 (2006). https://doi.org/10.2353/ajpath.2006.050754 PubMedPubMedCentralCrossRef

113.

L.A. Shimoda, S.S. Laurie, HIF and pulmonary vascular responses to hypoxia. J. Appl. Physiol. 116(7), 867–874 (2014). https://doi.org/10.1152/japplphysiol.00643.2013 PubMedCrossRef

114.

P.M. Hassoun, V. Thappa, M.J. Landman, B.L. Fanburg, Endothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells. Proc. Soc. Exp. Biol. Med. Soc. Exp. Biol. Med. 199(2), 165–170 (1992)CrossRef

115.

Y. Fan, L. Wang, C. Liu, H. Zhu, L. Zhou, Y. Wang, X. Wu, Q. Li, Local renin-angiotensin system regulates hypoxia-induced vascular endothelial growth factor synthesis in mesenchymal stem cells. Int. J. Clin. Exp. Pathol. 8(3), 2505–2514 (2015)PubMedPubMedCentral

116.

Y. Zhang, J. Lv, H. Guo, X. Wei, W. Li, Z. Xu, Hypoxia-induced proliferation in mesenchymal stem cells and angiotensin II-mediated PI3K/AKT pathway. Cell. Biochem. Funct. 33(2), 51–58 (2015). https://doi.org/10.1002/cbf.3080 PubMedCrossRef

117.

N.W. Morrell, P.D. Upton, M.A. Higham, M.H. Yacoub, J.M. Polak, J. Wharton, Angiotensin II stimulates proliferation of human pulmonary artery smooth muscle cells via the AT1 receptor. Chest 114(1 Suppl), 90S–91S (1998)PubMedCrossRef

118.

S. Krick, J. Hanze, B. Eul, R. Savai, U. Seay, F. Grimminger, J. Lohmeyer, W. Klepetko, W. Seeger, F. Rose, Hypoxia-driven proliferation of human pulmonary artery fibroblasts: cross-talk between HIF-1alpha and an autocrine angiotensin system. FASEB J. 19(7), 857–859 (2005). https://doi.org/10.1096/fj.04-2890fje PubMedCrossRef

119.

K.R. Stenmark, D. Bouchey, R. Nemenoff, E.C. Dempsey, M. Das, Hypoxia-induced pulmonary vascular remodeling: contribution of the adventitial fibroblasts. Physiol. Res. 49(5), 503–517 (2000)PubMed

120.

M. Humbert, N.W. Morrell, S.L. Archer, K.R. Stenmark, M.R. MacLean, I.M. Lang, B.W. Christman, E.K. Weir, O. Eickelberg, N.F. Voelkel, M. Rabinovitch, Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43(12 Suppl S), 13S–24S (2004). https://doi.org/10.1016/j.jacc.2004.02.029 PubMedCrossRef

121.

N.J. Davie, J.T. Crossno Jr., M.G. Frid, S.E. Hofmeister, J.T. Reeves, D.M. Hyde, T.C. Carpenter, J.A. Brunetti, I.K. McNiece, K.R. Stenmark, Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 286(4), L668–L678 (2004). https://doi.org/10.1152/ajplung.00108.2003 PubMedCrossRef

122.

M. Vogler, S. Vogel, S. Krull, K. Farhat, P. Leisering, S. Lutz, C.M. Wuertz, D.M. Katschinski, A. Zieseniss, Hypoxia modulates fibroblastic architecture, adhesion and migration: a role for HIF-1alpha in cofilin regulation and cytoplasmic actin distribution. PLoS. One 8(7), e69128 (2013). https://doi.org/10.1371/journal.pone.0069128 PubMedPubMedCentralCrossRef

123.

D.M. Gilkes, S. Bajpai, P. Chaturvedi, D. Wirtz, G.L. Semenza, Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J. Biol. Chem. 288(15), 10819–10829 (2013). https://doi.org/10.1074/jbc.M112.442939 PubMedPubMedCentralCrossRef

124.

S. Mizuno, H.J. Bogaard, N.F. Voelkel, Y. Umeda, M. Kadowaki, S. Ameshima, I. Miyamori, T. Ishizaki, Hypoxia regulates human lung fibroblast proliferation via p53-dependent and -independent pathways. Respir. Res. 10, 17 (2009). https://doi.org/10.1186/1465-9921-10-17 PubMedPubMedCentralCrossRef

125.

Y. Horino, S. Takahashi, T. Miura, Y. Takahashi, Prolonged hypoxia accelerates the posttranscriptional process of collagen synthesis in cultured fibroblasts. Life Sci. 71(26), 3031–3045 (2002)PubMedCrossRef

126.

L. Rosano, F. Spinella, A. Bagnato, Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 13(9), 637–651 (2013). https://doi.org/10.1038/nrc3546 PubMedCrossRef

127.

A. Bouallegue, G.B. Daou, A.K. Srivastava, Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr. Vasc. Pharmacol. 5(1), 45–52 (2007)PubMedCrossRef

128.

G.E. Morris, C.P. Nelson, N.B. Standen, R.A. Challiss, J.M. Willets, Endothelin signalling in arterial smooth muscle is tightly regulated by G protein-coupled receptor kinase 2. Cardiovasc. Res. 85(3), 424–433 (2010). https://doi.org/10.1093/cvr/cvp310 PubMedCrossRef

129.

M.B. Anand-Srivastava, Natriuretic peptide receptor-C signaling and regulation. Peptides 26(6), 1044–1059 (2005). https://doi.org/10.1016/j.peptides.2004.09.023 PubMedCrossRef

130.

N.E. Zois, E.D. Bartels, I. Hunter, B.S. Kousholt, L.H. Olsen, J.P. Goetze, Natriuretic peptides in cardiometabolic regulation and disease. Nat. Rev. Cardiol. 11(7), 403–412 (2014). https://doi.org/10.1038/nrcardio.2014.64 PubMedCrossRef

131.

K.N. Pandey, Guanylyl cyclase/natriuretic peptide receptor-A signaling antagonizes phosphoinositide hydrolysis, Ca(2+) release, and activation of protein kinase C. Front. Mol. Neurosci. 7, 75 (2014). https://doi.org/10.3389/fnmol.2014.00075 PubMedPubMedCentralCrossRef

132.

L.R. Potter, A.R. Yoder, D.R. Flora, L.K. Antos, D.M. Dickey, Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb. Exp. Pharmacol. 191, 341–366 (2009). https://doi.org/10.1007/978-3-540-68964-5_15 CrossRef

133.

D.F. Guo, Y.L. Sun, P. Hamet, T. Inagami, The angiotensin II type 1 receptor and receptor-associated proteins. Cell. Res. 11(3), 165–180 (2001). https://doi.org/10.1038/sj.cr.7290083 PubMedCrossRef

134.

S. Higuchi, H. Ohtsu, H. Suzuki, H. Shirai, G.D. Frank, S. Eguchi, Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin. Sci. 112(8), 417–428 (2007). https://doi.org/10.1042/CS20060342 PubMedCrossRef

135.

S. AbdAlla, H. Lother, A.M. Abdel-tawab, U. Quitterer, The angiotensin II AT2 receptor is an AT1 receptor antagonist. J. Biol. Chem. 276(43), 39721–39726 (2001). https://doi.org/10.1074/jbc.M105253200 PubMedCrossRef

136.

L. Gendron, M.D. Payet, N. Gallo-Payet, The angiotensin type 2 receptor of angiotensin II and neuronal differentiation: from observations to mechanisms. J. Mol. Endocrinol. 31(3), 359–372 (2003)PubMedCrossRef

137.

J.D. Stockand, Vasopressin regulation of renal sodium excretion. Kidney Int. 78(9), 849–856 (2010). https://doi.org/10.1038/ki.2010.276 PubMedCrossRef

138.

D.A. Ausiello, K.L. Skorecki, A.S. Verkman, J.V. Bonventre, Vasopressin signaling in kidney cells. Kidney Int. 31(2), 521–529 (1987)PubMedCrossRef

139.

J.D. Stockand, New ideas about aldosterone signaling in epithelia. American journal of physiology. Ren. Physiol. 282(4), F559–F576 (2002). https://doi.org/10.1152/ajprenal.00320.2001 CrossRef

140.

M. Briet, E.L. Schiffrin, Aldosterone: effects on the kidney and cardiovascular system. Nat. Rev. Nephrol. 6(5), 261–273 (2010). https://doi.org/10.1038/nrneph.2010.30 PubMedCrossRef

141.

C. Grossmann, M. Gekle, New aspects of rapid aldosterone signaling. Mol. Cell. Endocrinol. 308(1–2), 53–62 (2009). https://doi.org/10.1016/j.mce.2009.02.005 PubMedCrossRef

142.

R. Dooley, B.J. Harvey, W. Thomas, Non-genomic actions of aldosterone: from receptors and signals to membrane targets. Mol. Cell. Endocrinol. 350(2), 223–234 (2012). https://doi.org/10.1016/j.mce.2011.07.019 PubMedCrossRef

Title: Regulation, signalling and functions of hormonal peptides in pulmonary vascular remodelling during hypoxia
Authors: Priya Gaur
Supriya Saini
Praveen Vats
Bhuvnesh Kumar
Publication date: 01-03-2018
Publisher: Springer US
Published in: Endocrine / Issue 3/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1529-0

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

New insights on diabetes in Turner syndrome: results from an observational study in adulthood

The phosphodiesterase 5 inhibitor tadalafil regulates lipidic homeostasis in human skeletal muscle cell metabolism

Insulin and osteocalcin: further evidence for a mutual cross-talk

Correction to: Insulin and osteocalcin: further evidence for a mutual cross-talk

Impact of subclinical hypothyroidism with TSH ≤10 mIU/L on glomerular filtration rate in adult women without known kidney disease

The effect of vitamin D supplementation on thyroid autoantibody levels in the treatment of autoimmune thyroiditis: a systematic review and a meta-analysis

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage